Modern Biopharmaceuticals: Design, Development and Optimization 4 Volume Set

The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 120 such products are currently being marketed around the world, including nine blockbuster drugs, and nowadays represent the mainstay products of the biotechnology industry.
This book is unique in introducing readers to a comprehensive set of recently developed technologies, showing paradigm shifts in the health care system and reflecting these changes in industrial research.
Here, the world′s top scientists and business leaders divulge their first–hand expertise, allowing you to participate in their recent achievements. They all have their own specific contribution and have been carefully selected to provide a multifaceted and unique insight. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel laureates Robert Huber and Thomas R. Cech, as well as authors from the world′s most famous academic institutes and biotech companies, such as ETH Zurich, MIT, Stanford, Yale, Princeton, Harvard Medical School, Max–Planck–Institute, Fraunhofer–Institute, Moscow Academy of Sciences, London Imperial College and Baxter, Invitrogen, MorphoSys, Roche, and Schering AG.
The result is a testament to the importance of biotechnology in life science, a sure sign that "Modern Biopharmaceuticals" will fuel biotechnologies and help shape the industry of the future.
For pharmaceutists, pharmaceutical chemists, biochemists, molecular biologists, medicinal chemists, as well as those working in the biotechnological and pharmaceutical industries, or biotechnological institutes.

Spis treści:
VOLUME 1
Prologue.
Dedication.
Foreword.
Quotes.
Executive Summary.
List of Contributors.
Introduction.
Current Status of Biopharmaceuticals: Approved Products and Trends in Approvals (G. Walsh).
PART I: BIOP HARMACEUTICALS USED IN MOLECULAR MEDICINE.
From Genome to Clinic—Correlation Between Genes, Diseases and Biopharmaceuticals.
1. Beginning to Understand the End of the Chromosome (T. Cech).
2. The Role of Pharmacogenetic / Pharmacogenomics in Drug Development and Regulatory Review: Current Status (S. Huang & L. Lesko).
3. Large–scale Detection of Genetic Variation: The Key to Personalized Medicine (J. Geistlinger & P. Ahnert).
4. A System Biology Approach to Target Identification and Validation for Human Chronic Disease Drug Discovery (B. Rothberg, et al.).
5. The Development of Herceptin®: Paving the Way for Indivdualized Cancer Therapy (T. Gutjahr & C. Reinhardt).
siRNA—The Magic Bullet and Other Gene Therapeutical Approaches.
6. Adenovirus–based Gene Therapy: Therapeutic Angiogenesis with Adenovirus 5 Fibroblast Growth Factor–4 (Ad5FGF–4) in Patients with Chronic Myocardial Ischemia (M. McCaman, et al.).
7. MIDGE Vectors and dSLIM Immunomodulators: DNA–based Molecules for Gene Therapeutic Strategies (M. Scmidt, et al.).
8. Nonprotein–coding RNAs and their Potential as Biopharmaceuticals (M. Szymanski, et al.).
9. Double–stranded Decoy Oligonucleotides as New Biopharmaceuticals (A. Wagner & H. von der Leyen).
10. Rational siRNA Design for RNA Interference: Optimizations for Therapeutic Use and Current Applications (A. Khvorova, et al.).
Mobilis in Mobile—Human Embryonic Stem Cell and Other Sources for Cell Therapy.
11. The First Cloned Human Embryo: An Unlimited Source of Stem Cells for Therapeutic Cloning (W. Hwang, et al.).
12. Myocardial Regeneration Strategies Using Human Embryonic Stem Cells (I. Kehat, et al.).
13. Gene and Cell–based Therapies for Cardiovascular Disease (A. Mangi).
14. Spheramine®: A Cell Therapeutic Approach to Parkinson′s Disease (E. Reissig, et al.).
15. Applying Human Cell s to Organogenesis and Transplantation (B. Dekel & Y. Reisner).
VOLUME 2
PART II: BIOPHARMACEUTICALS AND THEIR MODE OF ACTION.
Quid pro Quo—Lysis vs. Coagulation in the Fine–tuned Balance of the Clotting Cascade.
1. Mechanisms of Serine Proteinase Activation: Insights for the Development of Biopharmaceuticals for Coagulation and Fibrinolysis (R. Friedrich).
2. Application of the Principle of Polyvalency to Protease Inhibition (L. Moroder).
3. A New Technology Standard for Safety and Efficacy in Factor VIII Replacement Therapy; Designing an Advanced Category rFVIII Concentrate (N. Riedel & F. Dorner).
Errare Humanum Est—What Causes Cancer and How to Selectively Fight Tumors.
4. Biopharmaceuticals Drugs From Natural Sources (D. Newman, et al.).
5. Biopharmaceutical as Targeting vehicles for In situ Radiotherapy of Malignancies (R. Reilly).
6. New Directions in Tumor Therapy—Amino Acid Deptetion with GlutaDON® as Treatment for Cancer (R. Kalhammer & N. Sethuraman).
Mundus Vult Decipi—High Mutation Rates of HIV and New Paradigms for Treatment.
7. AIDS Gene Therapy: A Vector Selectively Able to Destroy Latently HIV–1–infected Cells (F. Vázquez & R. Oya).
8. Combinatorial RNA–based Therapies for HIV–1 (K. Morris & J. Rossi).
PART III: IMPROVING THE DEVELOPMENT OF BIOPHARMACEUTICALS.
Citius, Altius, Fortius—Acceleration by High Throughput and Ultra–HT.
1. Design of Modern Biopharmaceuticals by Ultra–high–throughput Screening and Directed Evolution (M. Rarbach, et al.).
2. Learning from Viruses: High–throughput Cloning Using the Gateway® System to Transfer Genes without Restriction Enzymes (J. Chesnut).
In Vivo Veritas—Early Target Validation in Knock–out Mice and More.
3. Target Validation: An Important Early Step in the Development of Novel Biopharma ceuticals in the Post–genomic Era (C. Bagowski).
4. Genetically Modified Mice in Medical and Pharmaceutical Research (C. Brakebuch).
5. An NIH Model Organism for Biopharmaceutical and Biomedical Research: The Lower Eukayote Dictyostelium discoideum (T. Winckler, et al.).
Revolution by Evolution—Rational Design for Desire and Scientific Art of Optimization.
6. Releasing the Spring: Cofactor– and Substrate–assisted Activation of Factor IXa (H. Brandstette & K. Sichler).
7. Accelerating Diagnostic Product Development Process with Molecular Rational Design and Directed Evolution (H. Sobek, et al.).
VOLUME 3
PART IV: PRODUCTION OF BIOPHARMACEUTICALS.
The Industry′s Workhorses—Mammalian Expression System.
1. Manufacture of Recombinant Biopharmaceutical Proteins by Cultivated Mammalian Cells in Bioreactors (F. Wurm).
2. Alternative Strategies and New Cell Lines for High–level Production of Biopharmaceuticals (T. Rose, et al.).
3. PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins (C. Yallop, et al.).
4.  Use of the Glutamine Synthetase (GS) Expression System for the Rapid Development of Highly Productive Mammalian Cell Processes (J. Birch, et al.).
Vivat, Crescat, Floreat—A Ripe and Blooming Market for Transgenic Animals and Plants.
5. Biopharmaceuticals Derived from Transgenic Plants and Animals (J. Baez).
6. Production of Recombinant Proteins in Plants (V. Klimyuk, et al.).
7. Humanized Glycosylation: Production of Biopharmaceuticals in a Moss Bioreactor (G. Gorr & S. Wagner).
8. ExpressTec: High–level Expression of Biopharmaceuticals in Cereal Grains (N. Huang & D. Yang).
9. Biopharmaceutical Production in Cultured Plant Cells (S. Schillberg, et al.).
10. Producing Biopharmaceuticals in the Desert: Building an Abiotic Stress Tolerance in Plants for Salt, Heat, and Drought (S. Gepstein, et al.).
11. T